Premium
Characteristics of equine mesenchymal stem cells derived from amnion and bone marrow: In vitro proliferative and multilineage potential assessment
Author(s) -
LangeConsiglio A.,
Corradetti B.,
Meucci A.,
Perego R.,
Bizzaro D.,
Cremonesi F.
Publication year - 2013
Publication title -
equine veterinary journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.82
H-Index - 87
eISSN - 2042-3306
pISSN - 0425-1644
DOI - 10.1111/evj.12052
Subject(s) - mesenchymal stem cell , bone marrow , clonogenic assay , stromal cell , stem cell , amnion , progenitor cell , amniotic stem cells , biology , andrology , microbiology and biotechnology , cell , in vitro , immunology , adult stem cell , cancer research , medicine , endothelial stem cell , fetus , biochemistry , genetics , pregnancy
Summary Reasons for performing study This is the first study comparing stemness features of equine mesenchymal progenitor cells derived from amniotic membrane and bone marrow. Objectives To investigate an alternative and noninvasive stromal cell source for equine tissue engineering. Study design In vitro experimental study of the characteristics of equine mesenchymal progenitor cells derived from amnion and bone marrow. Methods Cells isolated from amniotic membrane and bone marrow were analysed for proliferation (growth curve, doubling time, colony forming unit). Immunocytochemical detection of pluripotency markers and gene expression of stromal cell markers were also performed and these cells were studied for multilineage plasticity. Results Amniotic stromal cells ( AMSC s) and bone marrow mesenchymal cells ( BM ‐ MSC s) both exhibited mature stromal cell‐specific gene expression and immunocytochemical properties, but showed substantial differences in their proliferative and differentiation potential. The mean doubling time for AMSC s was significantly lower (P<0.05) than that observed for BM ‐ MSC s (1.17 ± 0.15 vs. 3.27 ± 0.19 days, respectively). Compared to AMSC s, BM ‐ MSC s also demonstrated a significantly (P<0.05) lower clonogenic capability (one fibroblast‐like colony forming unit from a mean of 590.15 cells seeded for BM ‐ MSC s vs. 242.73 cells seeded for AMSC s). BM ‐ MSC s did not differentiate into glial cells, and the osteogenic differentiation process was longer than for AMSC s. Conclusions and potential relevance The amniotic membrane could be a valuable source of MSC s to be used both for allogenic and/or autologous therapies. The noninvasive nature and low cost of collection, the rapid proliferation along with a greater differentiation potential and the ‘off the shelf’ preparation potential could make AMC s useful for cell therapy.